reduces side effects

By Targets:	Apoptosis (2) Arrestin (1) Calcium Channel (1) Cannabinoid Receptor (1) DNA-PK (1) Drug-Linker Conjugates for ADC (2) Glucocorticoid Receptor (1) Hexokinase (1) Mineralocorticoid Receptor (1) NF-κB (1) Opioid Receptor (1)
By Research Areas:	Cancer (5) Inflammation/Immunology (1) Metabolic Disease (1) Neurological Disease (2)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-109017

Vamorolone VBP15	Glucocorticoid Receptor Mineralocorticoid Receptor NF-κB	Inflammation/Immunology
Vamorolone (VBP15) is a first-in-class, orally active dissociative steroidal anti-inflammatory agent and membrane-stabilizer. Vamorolone improves muscular dystrophy without side effects. Vamorolone shows potent NF-κB inhibition and substantially reduces hormonal effects .

HY-112340

CB1 antagonist 4	Cannabinoid Receptor	Metabolic Disease
CB1 antagonist 4 (compound 8) is a peripheral selective cannabinoid receptor type 1 (CB1) receptor antagonist. CB1 antagonist 4 shows limited penetrance to the brain in order to minimize or prevent CNS adverse reactions, and preserves potential antiobesity effects. CB1 antagonist 4 reduces propensity for psychiatric side effects .

HY-145736A

β-Glucuronide-dPBD-PEG5-NH2 TFA	Drug-Linker Conjugates for ADC Apoptosis	Cancer
β-Glucuronide-dPBD-PEG5-NH2 TFA is the β-glucuronide-linked pyrrolobenzodiazepine dimer, which binds to the prenylated antibody for synthesis of antibody-drug conjugate (ADC) cIRCR201-dPBD.β-glucuronide-linkage as a cleavable linker. β-Glucuronide-dPBD-PEG5-NH2 TFA, as a proagent of cIRCR201-dPBD, reduces side effects. β-Glucuronide-dPBD-PEG5-NH2 TFA can induce apoptosis and arrest cell cycle. β-Glucuronide-dPBD-PEG5-NH2 TFA has antitumor activity .

HY-145736

β-Glucuronide-dPBD-PEG5-NH2	Drug-Linker Conjugates for ADC Apoptosis	Cancer
β-Glucuronide-dPBD-PEG5-NH2 is the β-glucuronide-linked pyrrolobenzodiazepine dimer, which binds to the prenylated antibody for synthesis of antibody-drug conjugate (ADC) cIRCR201-dPBD. β-glucuronide-linkage as a cleavable linker. β-Glucuronide-dPBD-PEG5-NH2, as a proagent of cIRCR201-dPBD, reduces side effects. β-Glucuronide-dPBD-PEG5-NH2 can induce apoptosis and arrest cell cycle. β-Glucuronide-dPBD-PEG5-NH2 has antitumor activity .

HY-145600

Tegileridine	Opioid Receptor Arrestin	Neurological Disease
Tegileridine is the potent agonist of opioid receptor (MOR). Tegileridine is an oxa spiro derivative which reduces the side effects mediated by β-arrestin. Tegileridine has the potential for the research of pains and pains-related diseases (extracted from patent WO2017063509A1) .

HY-144036

DNA-PK-IN-3	DNA-PK	Cancer
DNA-PK-IN-3 is a potent inhibitor of DNA-PK. DNA-PK-IN-3 synergistically enhances the effect of radiotherapy and chemotherapy and effectively inhibits tumor growth. DNA-PK-IN-3 also effectively reduces the damage to normal cells and reducing side effects. DNA-PK-IN-3 has the potential for the research of cancer disease (extracted from patent WO2021213460A1, compound 4) .

HY-P5802

ω-Conotoxin FVIA	Calcium Channel	Neurological Disease
ω-Conotoxin FVIA is an N-type Ca ²⁺channel (Ca_v2.2) inhibitor. ω-Conotoxin FVIA reduces mechanical and thermal pain abnormalities in a rat model of caudal nerve injury. ω-Conotoxin FVIA can be used in the study of highly effective pain relievers with low side effects .

HY-125961

T3Inh-1	Others	Cancer
T3Inh-1 is a potent and selective inhibitor of ppGalNAc-T3 (IC₅₀=7 µM). T3Inh-1 reduces FGF23 hormone levels in both tissue cells and mice, without causing any toxic side effects. T3Inh-1 also prevents breast cancer cells. The enzyme ppGalNAc-T3 is implicated in at least two medically important pathways: cancer metastasis and stabilization of FGF23 (regulates phosphate levels in the bloodstream) .

HY-155008

PROTAC HK2 Degrader-1 1 Publications Verification	Hexokinase	Cancer
PROTAC HK2 Degrader-1 is a PROTAC consisting of Lonidamine (HY-B0486) as a target protein Hexokinase 2 (HK2) inhibitor and Thalidomide (HY-14658) as a CRBN ligand-linked PROTAC. PROTAC HK2 Degrader-1 selectively inhibits the proliferation of breast cancer cells by forming a ternary complex through the ubiquitin-proteasome system to degrade Hexokinase 2 (HK2) protein leading to mitochondrial damage and cell death. PROTAC HK2 Degrader-1 effectively inhibits breast tumor growth and reduces the colonic side effects of cisplatin for breast cancer research .

Cat. No.	Product Name

HY-L061

Orally Active Compound Library	3489 compounds
Most of the drugs that are available in the marketplace are administered via the oral route, which is a convenient and cost effective route of administration. Thus, oral bioavailability is one of the key considerations in drug design and development. A high oral bioavailability reduces the amount of an administered drug necessary to achieve a desired pharmacological effect and therefore could reduce the risk of side-effects and toxicity. A poor oral bioavailability can result in low efficacy and higher inter-individual variability and therefore can lead to unpredictable response to a drug. Low oral bioavailability in clinical trials is a major reason for drug candidates failing to reach the market. MCE offers a unique collection of 3489 compounds with confirmed high oral bioavailability. MCE Orally Active Compound Library is a useful tool for discovering new drugs with oral bioavailability.

Orally Active Compound Library

3489 compounds

Most of the drugs that are available in the marketplace are administered via the oral route, which is a convenient and cost effective route of administration. Thus, oral bioavailability is one of the key considerations in drug design and development. A high oral bioavailability reduces the amount of an administered drug necessary to achieve a desired pharmacological effect and therefore could reduce the risk of side-effects and toxicity. A poor oral bioavailability can result in low efficacy and higher inter-individual variability and therefore can lead to unpredictable response to a drug. Low oral bioavailability in clinical trials is a major reason for drug candidates failing to reach the market.

MCE offers a unique collection of 3489 compounds with confirmed high oral bioavailability. MCE Orally Active Compound Library is a useful tool for discovering new drugs with oral bioavailability.

Cat. No.	Product Name	Target	Research Area

HY-P5802

ω-Conotoxin FVIA	Calcium Channel	Neurological Disease
ω-Conotoxin FVIA is an N-type Ca ²⁺channel (Ca_v2.2) inhibitor. ω-Conotoxin FVIA reduces mechanical and thermal pain abnormalities in a rat model of caudal nerve injury. ω-Conotoxin FVIA can be used in the study of highly effective pain relievers with low side effects .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Peptides

Name
Email *

	Sorry, but the email address you supplied was invalid.